Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cel...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090141&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849720581994315776 |
|---|---|
| author | Henrica M J Werner Jone Trovik Mari K Halle Elisabeth Wik Lars A Akslen Even Birkeland Therese Bredholt Ingvild L Tangen Camilla Krakstad Helga B Salvesen |
| author_facet | Henrica M J Werner Jone Trovik Mari K Halle Elisabeth Wik Lars A Akslen Even Birkeland Therese Bredholt Ingvild L Tangen Camilla Krakstad Helga B Salvesen |
| author_sort | Henrica M J Werner |
| collection | DOAJ |
| description | Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cell lines before and after stathmin knock-down. Subsequently we investigated the clinical response to paclitaxel containing chemotherapy in metastatic endometrial cancer in relation to stathmin protein level in tumors. Stathmin level was also determined in metastatic lesions, analyzing changes in biomarker status on disease progression. Knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel. In clinical samples, high stathmin level was demonstrated to be associated with poor response to paclitaxel containing chemotherapy and to reduced disease specific survival only in patients treated with such combination. Stathmin level increased significantly from primary to metastatic lesions. This study suggests, supported by both preclinical and clinical data, that stathmin could be a predictive biomarker for response to paclitaxel treatment in endometrial cancer. Re-assessment of stathmin level in metastatic lesions prior to treatment start may be relevant. Also, validation in a randomized clinical trial will be important. |
| format | Article |
| id | doaj-art-07ba8361bca64583ae419e4e7efe5a91 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-07ba8361bca64583ae419e4e7efe5a912025-08-20T03:11:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0192e9014110.1371/journal.pone.0090141Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.Henrica M J WernerJone TrovikMari K HalleElisabeth WikLars A AkslenEven BirkelandTherese BredholtIngvild L TangenCamilla KrakstadHelga B SalvesenStathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cell lines before and after stathmin knock-down. Subsequently we investigated the clinical response to paclitaxel containing chemotherapy in metastatic endometrial cancer in relation to stathmin protein level in tumors. Stathmin level was also determined in metastatic lesions, analyzing changes in biomarker status on disease progression. Knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel. In clinical samples, high stathmin level was demonstrated to be associated with poor response to paclitaxel containing chemotherapy and to reduced disease specific survival only in patients treated with such combination. Stathmin level increased significantly from primary to metastatic lesions. This study suggests, supported by both preclinical and clinical data, that stathmin could be a predictive biomarker for response to paclitaxel treatment in endometrial cancer. Re-assessment of stathmin level in metastatic lesions prior to treatment start may be relevant. Also, validation in a randomized clinical trial will be important.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090141&type=printable |
| spellingShingle | Henrica M J Werner Jone Trovik Mari K Halle Elisabeth Wik Lars A Akslen Even Birkeland Therese Bredholt Ingvild L Tangen Camilla Krakstad Helga B Salvesen Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS ONE |
| title | Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. |
| title_full | Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. |
| title_fullStr | Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. |
| title_full_unstemmed | Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. |
| title_short | Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. |
| title_sort | stathmin protein level a potential predictive marker for taxane treatment response in endometrial cancer |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090141&type=printable |
| work_keys_str_mv | AT henricamjwerner stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT jonetrovik stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT marikhalle stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT elisabethwik stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT larsaakslen stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT evenbirkeland stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT theresebredholt stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT ingvildltangen stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT camillakrakstad stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT helgabsalvesen stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer |